Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 224

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Open access
Limagne, Emeric, Nuttin, Lisa, Thibaudin, Marion, Jacquin, Elise, Aucagne, Romain, Bon, Marjorie, Revy, Solène, Barnestein, Robby, Ballot, Elise, Truntzer, Caroline, Derangère, Valentin, Fumet, Jean-David, Latour, Charlène, Rébé, Cédric, Bellaye, Pierre-Simon, Kaderbhaï, Coureche-Guillaume, Spill, Aodrenn, Collin, Bertrand, Callanan, Mary B., Lagrange, Aurélie, Favier, Laure, Coudert, Bruno, Arnould, Laurent, Ladoire, Sylvain, Routy, Bertrand, Joubert, Philippe, Ghiringhelli, François · 2022 · Cancer Cell

Abstract

Chemotherapy with anti PD-1/PD-L1 antibodies has become the standard of care for patients with metastatic non-small cell lung cancer (mNSCLC). Using lung tumor models, where pemetrexed and cisplatin (PEM/CDDP) chemotherapy remains unable to synergize with immune checkpoint inhibitors (ICIs), we linked the failure of this treatment with its inability to induce CXCL10 expression and CD8+ T cell recruitment. Using drug screening, we showed that combining a MEK inhibitor (MEKi) with PEM/CDDP triggers CXCL10 secretion by cancer cells and CD8+ T cell recruitment, sensitizing it to ICIs. PEM/CDDP plus a MEKi promotes optineurin (OPTN)-dependent mitophagy, resulting in CXCL10 production in a mitochondrial DNA- and TLR9-dependent manner. TLR9 or autophagy/mitophagy inhibition abolishes the anti-tumor efficacy of PEM/CDDP plus MEKi/anti-PD-L1 therapy. In human NSCLCs, high OPTN, TLR9, and CXCL10 expression is associated with a better response to ICIs. Our results underline the role of TLR9- and OPTN-dependent mitophagy in enhancing chemoimmunotherapy efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2021.12.009

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 28 references

Cited by

See all 224

Metadata

Authors
Limagne, E., Nuttin, L., Thibaudin, M., Jacquin, E., Aucagne, R., Bon, M., Revy, S., Barnestein, R., Ballot, E., Truntzer, C., Derangère, V., Fumet, J.-D., Latour, C., Rébé, C., Bellaye, P.-S., Kaderbhaï, C.-G., Spill, A., Collin, B., Callanan, M. B., Lagrange, A., Favier, L., Coudert, B., Arnould, L., Ladoire, S., Routy, B., Joubert, P., & Ghiringhelli, F.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2022-02
Volume
40
Issue
2
Pages
136-152.e12
ISSN
1535-6108 (ISSN-L)
OpenAlex
W4205491929
Cited by
224
References
28
FWCI
17.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. https://app.cochat.ai/papers/10.1016/j.ccell.2021.12.009
The paper
Limagne, E., Nuttin, L., Thibaudin, M., Jacquin, E., Aucagne, R., Bon, M., Revy, S., Barnestein, R., Ballot, E., Truntzer, C., Derangère, V., Fumet, J.-D., Latour, C., Rébé, C., Bellaye, P.-S., Kaderbhaï, C.-G., Spill, A., Collin, B., Callanan, M. B., . . . Ghiringhelli, F. (2022). MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer Cell. https://doi.org/10.1016/j.ccell.2021.12.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.